Form 4: Dyne Therapeutics Executive Sells Shares to Cover Tax Obligations

Oxana Beskrovnaya, Chief Scientific Officer of Dyne Therapeutics, sold shares to cover tax obligations related to vesting restricted stock units.

Summary

• Oxana Beskrovnaya, the Chief Scientific Officer of Dyne Therapeutics, sold 2,222 shares of common stock on May 16, 2024, at a weighted average price of $28.2.
• She also sold 483 shares on the same day at a weighted average price of $28.59.
• These sales were to cover tax withholding obligations related to the vesting of restricted stock units.
• The sales were executed under a pre-arranged plan (Rule 10b5-1) entered into on January 25, 2024.
• Following these transactions, Beskrovnaya directly owns 149,647 shares of Dyne Therapeutics, which includes 130,308 unvested RSUs.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing simply reports a routine stock sale for tax purposes under a pre-existing plan. It doesn't inherently indicate positive or negative sentiment about the company's future prospects.

Industry Context

Insider sales, especially those related to tax obligations, are common and don't necessarily indicate a negative outlook for the company. It's important to consider the context of the sale, such as the existence of a pre-arranged trading plan.

Stakeholder Impact

• The stock sale may have a minor, temporary impact on shareholders due to the increased supply of shares in the market.

Key Dates